HPBCD treatment of Alzheimer’s disease

Posted by

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that it has filed a patent application titled “Methods for Treating Alzheimer’s Disease.”

The patent application covers dosing regimens and routes of administration. The patent application lists co-inventors Sharon H. Hrynkow, PhD, Jeffrey L. Tate, PhD, and N. Scott Fine of CTD Holdings.

Hydroxypropyl beta cyclodextrin (HPBCD) has been shown in animal models and cell culture to reduce the formation of amyloid beta, one of the hallmarks of Alzheimer’s Disease.

CTD currently collaborates with the Kerwin Research Center to provide HPBCD intravenously to a single patient with late-onset Alzheimer’s Disease on an Expanded Access basis (ClinicalTrials.gov NCT03624842).



Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.